U-M Cancer Center research included in ASCO’s annual honor roll
8:51 am in Cancer Research, Cancer Treatment, Clinical Trials, Prostate Cancer by mCancer Partner
The American Society of Clinical Oncology recently highlighted research by Maha Hussain, M.D., associate director for clinical research at the University of Michigan Comprehensive Cancer Center, as one of the top advances in cancer of the year. It was featured in the “Clinical Cancer Advances 2011: ASCO’s Annual Report on Progress Against Cancer,” which was published in a recent issue of the Journal of Clinical Oncology.
Maha Hussain, M.D.
The report is an annual, independent review of advances in cancer research that have had the greatest impact on patient care. Clinical Cancer Advances 2011 includes 54 significant studies, including 12 that the report’s editors consider major advances.
Hussain’s study, “Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial,” showed early promise for the drug Cabozantinib in treating prostate cancer, particularly in cases where tumors had spread to bone.
Read more about the study’s findings at mCancer.org. Or download the ASCO report at Cancer.net.
